Article Details

SUDA Pharmaceuticals licenses novel iNKT cell therapy platform from Imperial College London

Retrieved on: 2021-06-18 02:15:00

Tags for this article:

Click the tags to see associated articles and topics

SUDA Pharmaceuticals licenses novel iNKT cell therapy platform from Imperial College London. View article details on hiswai:

Excerpt

“Only ASX-listed CAR-iNKT company”. SUDA CEO and managing director Dr Michael Baker said: “Cell therapies have transformed the way we think ...

Article found on: www.proactiveinvestors.co.uk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up